Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
The latest announcement is out from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ).
Hemogenyx Pharmaceuticals has filed an amendment with the FDA to include pediatric patients in its Phase I clinical trial of HG-CT-1, a CAR-T therapy for relapsed/refractory acute myeloid leukemia (R/R AML). This expansion aims to address the critical unmet medical need in pediatric oncology, reflecting the company’s commitment to broadening the impact of its therapies and supporting the potential of HG-CT-1 as a transformative treatment for AML.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded, clinical-stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 38,802
Technical Sentiment Signal: Sell
Current Market Cap: £7.48M
Learn more about HEMO stock on TipRanks’ Stock Analysis page.